Results of Treatment of Patients with Multiple Drug Resistant Tuberculosis among Key Populations during the COVID-19 Pandemic in Dushanbe, Tajikistan

Q4 Medicine
Z. Tilloeva, A. S. Mirzoev
{"title":"Results of Treatment of Patients with Multiple Drug Resistant Tuberculosis among Key Populations during the COVID-19 Pandemic in Dushanbe, Tajikistan","authors":"Z. Tilloeva, A. S. Mirzoev","doi":"10.58838/2075-1230-2024-102-3-24-33","DOIUrl":null,"url":null,"abstract":"The objective: to identify changes in effectiveness of treatment of multiple drug resistant tuberculosis among key populations in Dushanbe, including the period of the COVID-19 pandemic.Subjects and Methods. Retrospective study of medical records of 431 MDR TB patients registered for treatment in Dushanbe was conducted (2017-2019 - Group 1 and 2020-2021 - Group 2 (the COVID-19 pandemic period)).Results. The duration of treatment was 15.4±6.9 months in Group 1, and 10.8±4.3 months in Group 2, which was due to the introduction of short-course regimens in that group. At the same time, in Group 2 there was an increase in effectiveness of MDR TB treatment to 85% versus 80% in Group 1, which was due to the use of new drugs and regimens containing them. In Group 1, a statistically significant association was found between MDR TB treatment failure and the following parameters: male gender (RR=2.3 (1.36-4.04), p=0.002), positive HIV status (RR=2.35 (1.37-4.05), p=0.011), hepatitis C infection (RR=3.0 (1.87-4.8), p <0.001), alcohol (RR=3.2 (1.96-5.2), p<0.001) and substances abuse (RR=3.99 (2.5-6.2), p<0.001), previous imprisonment (RR=2.6 (1.48-4.6), p<0.001), unemployment (RR=3.5 (1.8-6.7), p <0.001), and homelessness (RR=5.0 (3.9-6.5), p=0.0011). In Group 2, failure of MDR TB treatment was statistically significantly associated with hepatitis C (RR=3.3 (1.5-7.2), p=0.02), alcohol and drug abuse (RR= 4.4 ( 1.95-10.1). p =0.026), as well as (unlike Group 1) labor migration (RR=3.0 (1.45-6.2), p=0.0068), in-patient treatment (RR=3.8 (1.36-10.64), p=0.0056), while there was no association with HIV status.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Lung Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58838/2075-1230-2024-102-3-24-33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The objective: to identify changes in effectiveness of treatment of multiple drug resistant tuberculosis among key populations in Dushanbe, including the period of the COVID-19 pandemic.Subjects and Methods. Retrospective study of medical records of 431 MDR TB patients registered for treatment in Dushanbe was conducted (2017-2019 - Group 1 and 2020-2021 - Group 2 (the COVID-19 pandemic period)).Results. The duration of treatment was 15.4±6.9 months in Group 1, and 10.8±4.3 months in Group 2, which was due to the introduction of short-course regimens in that group. At the same time, in Group 2 there was an increase in effectiveness of MDR TB treatment to 85% versus 80% in Group 1, which was due to the use of new drugs and regimens containing them. In Group 1, a statistically significant association was found between MDR TB treatment failure and the following parameters: male gender (RR=2.3 (1.36-4.04), p=0.002), positive HIV status (RR=2.35 (1.37-4.05), p=0.011), hepatitis C infection (RR=3.0 (1.87-4.8), p <0.001), alcohol (RR=3.2 (1.96-5.2), p<0.001) and substances abuse (RR=3.99 (2.5-6.2), p<0.001), previous imprisonment (RR=2.6 (1.48-4.6), p<0.001), unemployment (RR=3.5 (1.8-6.7), p <0.001), and homelessness (RR=5.0 (3.9-6.5), p=0.0011). In Group 2, failure of MDR TB treatment was statistically significantly associated with hepatitis C (RR=3.3 (1.5-7.2), p=0.02), alcohol and drug abuse (RR= 4.4 ( 1.95-10.1). p =0.026), as well as (unlike Group 1) labor migration (RR=3.0 (1.45-6.2), p=0.0068), in-patient treatment (RR=3.8 (1.36-10.64), p=0.0056), while there was no association with HIV status.
塔吉克斯坦杜尚别 COVID-19 大流行期间主要人群中多重耐药结核病患者的治疗结果
目的:确定杜尚别重点人群耐多药结核病治疗效果的变化,包括COVID-19大流行期间。对杜尚别市登记治疗的 431 名多重耐药结核病患者的医疗记录进行了回顾性研究(2017-2019 年--第一组和 2020-2021 年--第二组(COVID-19 大流行期间))。第 1 组患者的治疗时间为(15.4±6.9)个月,第 2 组患者的治疗时间为(10.8±4.3)个月,这是因为该组采用了短程治疗方案。与此同时,第 2 组 MDR 结核病的治疗有效率从第 1 组的 80%提高到 85%,这是因为使用了新药和含有新药的治疗方案。在第 1 组中,MDR TB 治疗失败与以下参数之间存在统计学意义上的显著关联:男性(RR=2.3(1.36-4.04),P=0.002)、HIV 阳性(RR=2.35(1.37-4.05),P=0.011)、丙型肝炎感染(RR=3.0(1.87-4.8),P<0.001)、酒精(RR=3.2(1.96-5.2),P<0.001)和药物滥用(RR=3.99(2.5-6.2),P<0.001)、曾入狱(RR=2.6(1.48-4.6),P<0.001)、失业(RR=3.5(1.8-6.7),P<0.001)和无家可归(RR=5.0(3.9-6.5),P=0.0011)。在第 2 组中,MDR TB 治疗失败与丙型肝炎(RR=3.3 (1.5-7.2),P=0.02)、酗酒和吸毒(RR=4.4 ( 1.95-10.1).026),以及(与第 1 组不同的是)劳动力迁移(RR=3.0(1.45-6.2),p=0.0068)、住院治疗(RR=3.8(1.36-10.64),p=0.0056),而与艾滋病毒感染状况没有关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tuberculosis and Lung Diseases
Tuberculosis and Lung Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.20
自引率
0.00%
发文量
88
审稿时长
8 weeks
期刊介绍: The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions. The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信